



JEA BizDev Consulting Advises NovaRock Biotherapeutics on Partnership with LigaChem Biosciences

CLIENT SHOWCASE

February 24, 2026

[JEA BizDev Consulting, LLC](#) advised NovaRock Biotherapeutics, Inc., on an out-licensing agreement with LigaChem Biosciences for an ADC candidate targeting a novel oncology antigen. Under the agreement, NovaRock granted LigaChem exclusive global rights to develop and commercialize ADCs incorporating this antibody.

JEA BizDev Consulting served as lead business development and transaction advisor to NovaRock Biotherapeutics on this strategic partnership. The deal includes a license fee, clinical and regulatory milestones, sublicense revenue sharing, and royalties. Financial terms of the license agreements were not disclosed.

The JEA BizDev Consulting team was led by [John Adamou](#), President and Managing Director.

For more information, please refer to the [news release](#).